Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Safety and Immunogenicity of Three Consistency Lots and a High-Dose Lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in Healthy Adults (V920-012)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Not of reproductive potential, or of reproductive potential and agrees to avoid becoming pregnant or impregnating a partner for 2 months following study vaccination.~Exclusion Criteria:~* Is currently participating in or has participated in an interventional clinical trial with an investigational compound or device within 90 days of participation in this trial.~* Has previously been randomized in another clinical trial and received V920 or any other Ebola vaccine.~* Has been exposed to Ebola virus at any time prior to study entry.~* Is pregnant or breastfeeding or plans to conceive within 2 months following study vaccination.~* Has direct household exposure to a pregnant or lactating woman at the time of participation in this trial.~* Has had a fever (≥100.5ºF/38.0ºC) within 48 hours prior to study entry.~* Has received systemic corticosteroids (equivalent of ≥2 mg/kg total daily dose of prednisone or ≥20 mg/day for persons weighing \>10 kg) for ≥14 consecutive days and has not completed treatment at least 30 days prior to study entry.~* Has received systemic corticosteroids exceeding physiologic replacement doses (\~5 mg/day prednisone equivalent) within 14 days prior to study entry.~* Has received any live virus vaccine within 30 days prior to study entry or any other (nonlive virus) vaccine within 14 days prior to study entry.~* Has known or suspected impairment of immunological function (e.g., HIV positive).~* Has direct household exposure to a person with known or suspected impairment of immunological function (e.g., HIV positive).~* Has a clinically significant history of intravenous (IV) drug abuse within 12 months prior to study entry.~* Has a known allergy/sensitivity or contraindication to investigational product(s) or its/their excipients (e.g., albumin).~* Has a history of malignancy \<=5 years prior to study entry except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.~* Is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- V920 Consistency Lot A (Type: EXPERIMENTAL): Participants received a 1.0 mL intramuscular injection of V920 on Day 1
- V920 Consistency Lot B (Type: EXPERIMENTAL): Participants received a 1.0 mL intramuscular injection of V920 on Day 1
- V920 Consistency Lot C (Type: EXPERIMENTAL): Participants received a 1.0 mL intramuscular injection of V920 on Day 1
- V920 High-dose Lot (Type: EXPERIMENTAL): Participants received a 1.0 mL intramuscular injection of V920 on Day 1
- Placebo to V920 (Type: PLACEBO_COMPARATOR): Participants received a 1.0 mL intramuscular injection of placebo on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete